Eli Lilly and Company $LLY is Meadow Creek Wealth Advisors LLC's 10th Largest Position

Key Points

• Meadow Creek Wealth Advisors LLC increased its stake in Eli Lilly and Company by 129.8%, making it the firm's 10th largest position, with holdings now valued at approximately $3.08 million.
• Eli Lilly's stock ratings are generally positive, with one Strong Buy, fifteen Buy ratings, and nine Hold ratings, and an average price target of $938.61 according to recent analyst reports.
• The company reported $6.31 EPS for the last quarter, significantly exceeding expectations, and projected annual earnings of $21.75 - $23.00 EPS for FY 2025.

Meadow Creek Wealth Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 129.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,960 shares of the company's stock after buying an additional 2,237 shares during the quarter. Eli Lilly and Company makes up about 2.1% of Meadow Creek Wealth Advisors LLC's holdings, making the stock its 10th biggest position. Meadow Creek Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $3,087,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in LLY. Hobbs Wealth Management LLC raised its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after buying an additional 12 shares during the last quarter. Hixon Zuercher LLC lifted its stake in shares of Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the period. O Brien Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares during the last quarter. Ascent Capital Management LLC increased its stake in Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the last quarter. Finally, Willner & Heller LLC lifted its position in Eli Lilly and Company by 1.5% during the first quarter. Willner & Heller LLC now owns 854 shares of the company's stock worth $705,000 after buying an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. Erste Group Bank raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Tuesday, October 14th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Morgan Stanley lowered their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday, October 3rd. Weiss Ratings restated a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Finally, BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an "outperform" rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $938.61.

Eli Lilly and Company Trading Down 1.1%

NYSE LLY opened at $799.85 on Wednesday. The stock has a market cap of $757.03 billion, a P/E ratio of 52.28, a PEG ratio of 1.16 and a beta of 0.47. The company's fifty day simple moving average is $759.77 and its 200-day simple moving average is $766.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.14% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.